<DOC>
	<DOCNO>NCT02808208</DOCNO>
	<brief_summary>The aim phase 1 study determine role autologous adipose derive mesenchymal stem cell reduction hemodialysis arteriovenous fistula failure apply time surgical creation .</brief_summary>
	<brief_title>Autologous Adipose Derived Mesenchymal Stem Cells ( AMSC ) Reducing Hemodialysis Arteriovenous Fistula Failure</brief_title>
	<detailed_description />
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Fistula</mesh_term>
	<mesh_term>Arteriovenous Fistula</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Inclusion Criteria Patient 18 85 year old Patient currently hemodialysis plan creation upper extremity AV fistula suitable anatomy Hemoglobin ≥ 8 g/dL platelet count ≥ 100,000/mm3 prior surgery ( Day 0 ) Other hematological biochemical parameter within range consistent ESRD acceptable administration general anesthesia prior day 1 Adequate liver function , define serum bilirubin ≤ 1.5 mg/dL ; GGT , AST , ALT , alkaline phosphatase ≤ 2x upper limit normal INR ≤ 1.5 prior day 1 INR ≤ 2 ( 2.5 certain condition ) anticoagulant therapy . Ability communicate meaningfully investigative staff , competence give write informed consent , ability comply entire study procedure Life expectancy least 24 month Exclusion Criteria History evidence severe cardiac disease ( NYHA Functional Class III IV ) , myocardial infarction within 6 month entry , ventricular tachyarrhythmias require continue treatment , unstable angina Significant uncontrolled hypertension ( systolic blood pressure 160 mm Hg and/or diastolic blood pressure 100 mm Hg ) History evidence severe peripheral vascular disease upper limbs know suspected central vein obstruction side plan fistula creation Stroke within six ( 6 ) month study entry Treatment vitamin Kantagonists direct thrombin inhibitor INR ≥ 2 Malignancy treatment malignancy within previous 6 month Immunodeficiency include AIDS / HIV Active autoimmune disease Documented hypercoagulable state history 2 DVTs spontaneous intravascular thrombotic event Bleeding diathesis Gastrointestinal ulcer bleeding , wind dehiscence A prothrombin time partial thromboplastin time 1.2 time upper limit normal , absolute platelet count low limit normal ; absolute neutrophil count 1,500/mm3 Active local systemic infection ( WBC &gt; 15,000/mm3 ) anemia hematocrit le 30 % Previous autogenous fistula operative limb unless AVF place proximally previous fail fistula 1 fail AVF operative limb Known serious allergy aspirin penicillin Pregnancy breast feeding Treatment investigational drug/ device within 60 day prior study entry Any condition judgment investigator would preclude adequate evaluation safety efficacy AMSCs AVF Employees sponsor patient employee relative investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>